The US Air Force seeks to commercialize through patent licensing a trauma specific vascular injury shunt to restore blood flow to an injured extremity until definitive vascular repair can be accomplished.
The 59th Medical Wing conducted the research to develop the original technology and is the USAF
partner for advanced development to field this technology.
Extremity vascular injury results in bleeding and lack of blood flow beyond the site of vessel disruption (ischemia). Priorities in this setting include hemorrhage control, management of life-threatening injuries, and restoration of flow to the extremity. While definitive vessel repair is optimal, austere conditions, life threatening injuries, and Medevac often prohibit this option. Alternatively a temporary vascular shunt (a small caliber hollow plastic tube) may be placed in the uninjured segments of vessel above and below the disruption to restore blood flow until conditions improve and the shunt can be removed and repair performed. Wartime and civilian reports confirm the effectiveness of vascular shunts; however, at present their use is a nascent art. Current shunts were designed by vascular and neurosurgeons for use in age related vascular disease and not injury. As such existing technology is suboptimal for vascular injury.
The US Air Force has developed a trauma-specific vascular injury shunt (TS-VIS), which represents a breakthrough in the management of extremity vascular injury. The device has been designed by combat surgeons and military researchers to allow this capability to be applied in different operational environments including civilian and wartime. Its features also minimize the risk of complications, ensure its adaptability to the unique needs of patients, and allow infusion of therapeutic (therapeutic reperfusion) or contrast agents (angiography) into the injured limb.
• Safe: Designed for convenient, rapid insertion by broad range of surgeons and to lessen complication risks
• Effective: Early reperfusion of damaged extremity leads to improved functional outcomes for patients
• Game-changing: First shunt designed for extremity vascular injury
• US Patent 8,251,943 is available for license
• Systematic preclinical studies published in peer-reviewed journals have demonstrated efficacy and safety of early restoration of extremity perfusion using this technique. Porcine studies and capabilities document also available for review.
• Licensing and commercialization/development partner(s) sought
The opinions expressed on this document are solely those of the author(s) and do not represent an endorsement by or the views of the United States Air Force, the Department of Defense, or the United States Government.